Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. (Nasdaq: CELU) on March 5, 2026, reporting events that occurred on February 27, 2026. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On February 27, 2026, the Company experienced a significant change in its executive leadership:
- Departure: Joseph DosSantos, Senior Vice President of Finance and Acting Chief Financial Officer, left the Company for personal reasons.
- Appointment: John Sprague was appointed as the new Acting Chief Financial Officer effective February 27, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of the officer transition under Item 5.02.
Investor Verification Checklist
- Verify the background and qualifications of the new Acting CFO, John Sprague.
- Confirm the effective date of the transition to ensure no gap in financial oversight.
- Review subsequent filings for any impact on the company's financial reporting timeline or internal controls due to the leadership change.